To:

Head of Paediatric Medicines
European Medicines Agency
30 Churchill Place
London E14 5EU
United Kingdom
paediatrics@ema.europa.eu

Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision

Gilead Submission Reference: 5745-16-224

Actives substances(s): GS-5745

Invented name: N/A

Latest Decision number(s): 1) P/0146/2016

Corresponding PIP number(s): 1) EMEA-001813-PIP01-15

Please note that development of the medicinal product above in the [condition(s)/indication(s)]:

Treatment of ulcerative colitis

Treatment of Crohn's disease

☒ has been discontinued

☐ has been suspended/put on long-term hold (with possible re-start at a later time)

for the following reason(s): (tick all that apply)

☒ (possible) lack of efficacy in adults

☐ (possible) lack of efficacy in children

☐ (possible) unsatisfactory safety profile in adults

☐ (possible) unsatisfactory safety profile in children

☐ commercial reasons (please specify:)

☐ manufacturing / quality problems

☐ other regulatory action (please specify:) (e.g. suspension, revocation of M.A.)

☐ other reason (please specify:)

Please add a brief description (max 2000 characters) of the reason(s) for the discontinuation / suspension:

As per protocol for Study GS-US-326-1100 (a combined phase 2/3, double-blind, randomized, placebo-controlled, induction and maintenance study evaluating the safety and efficacy of GS-5745 in subjects with moderately to severely active ulcerative colitis), Gilead requested the DMC conduct a futility analysis after 150 subjects were randomized and treated for the 8 week induction period. Endoscopic data were reviewed by the independent DMC and based on pre-specified efficacy criteria the DMC communicated to Gilead that both doses of study drug should not be continued. Effective 21 September 2016 Gilead has therefore discontinued the study on the grounds of lack of efficacy.

As described in the protocol, after all subjects were enrolled into the GS-US-395-1663 Study (a phase 2, double-blind, randomized, placebo-controlled, multicenter study evaluating the safety and efficacy of GS-5745 in subjects with moderately to severly active Crohn's diease), an analysis to evaluate clinical response, defined as PRO-2 score ≤8, and endoscopic response, defined as reduction in the SES-CD of ≥50% from baseline, at week 8 was conducted. On 27 October 2016, review of the clinical and endoscopic response criteria concluded that there is inadequate efficacy of GS-5745 compared to placebo in these areas. As a consequence, effective 1 November 2016 the GS-US-395-1663 Study was terminated.

No safety concerns were noted for any of these studies.

No further development of GS-5745 in the treatment of ulcerative colitis or Crohn's disease is planned.

Name and signature of the PIP contact point:

Neil Roberts

Date: 10 November 2016

Contact for inquiries from interested parties:

Telephone: +44-1223-897300

Email: regulatory.pip@gilead.com